Profile

Liver - Market Overview

Tissera expects that implants of liver-precursor tissue will provide a suitable therapy for a range of liver applications. The cost savings, not to mention the improvement in quality of life, from a successful transplantation procedure that would eliminate the need for alternative factor replacement and frequent medical treatments would be substantial. Within four years of market introduction, Tissera estimates that 4,000 hemophiliacs (out of more than 50,000 worldwide) would opt for this procedure. This would indicate a market size of approximately $120 million. The Company estimates that about 3,000 of those being treated for familial hypercholesterolemia and who are not responsive to drug treatment will opt for treatment in the fourth year in the market. Eventually, the market for metabolic diseases might reach 10,000 patients per year, implying a market potential of $300 million.

Back to Top È

Pancreas Market Overview

Diabetes afflicts nearly 140 million people worldwide and this figure is expected to increase to almost 300 million by the year 2025. In the United States alone, 17.0 million people (6.2% of the population) have diabetes. Diagnosed: 11.1 million people Undiagnosed: 5.9 million people.

Diabetes is the 7th leading cause of death in the United States and is associated with long-term complications that affect almost every part of the body. The American Diabetes Association study survey estimated direct and indirect medical expenditures attributable to diabetes in the United States at $132 billion (Updated May 2003) [1] Type I insulin dependent diabetes accounts for between 5% and 10% of the total number of diabetes patients.

Of the 17.0 million people with diabetes in the U.S., about one million suffer from type I diabetes. Tissera estimate this would represent a $2.0 billion per year market. Tissera's treatment is expected to use minimally invasive laparoscopic surgery and to require far less immunosuppressive drugs than current islet cell or full pancreas transplants. The worldwide market including type II diabetes patients could be $10 billion.

[1]: http://www.cdc.gov/diabetes/pubs/estimates.htm#costs

Back to Top È

Kidney Market Overview

Average Medicare payments for dialysis patients is about $53,400 per year. A kidney transplant costs, on average, over $70,000 and organ acquisition is estimated at around $20,000. The average Medicare payment for care of a transplant patient (immunosuppressive drugs and medical monitoring) is about $17,200 per year such that the cost of transplantation is covered by savings in dialysis costs in about three years.[1]

Given one hundred thousand new cases of end-stage renal disease each year, this would indicate a potential $2 billion U.S. market. The potential world market would be two to three times that size.

[1] U.S. Renal Data System, USRDS 2002 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2002.

Back to Top È